OZAGREL SODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H11N2O2.Na
Molecular Weight	250.2284
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[O-]C(=O)\C=C\C1=CC=C(CN2C=CN=C2)C=C1

InChI

InChIKey=NCNYJCOBUTXCBR-IPZCTEOASA-M

InChI=1S/C13H12N2O2.Na/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15;/h1-8,10H,9H2,(H,16,17);/q;+1/p-1/b6-5+;

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C13H11N2O2
Molecular Weight	227.2386
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: http://www.pathophysiologyjournal.com/article/S0928-4680(97)00013-8/pdf | http://www.ncbi.nlm.nih.gov/pubmed/14720071 | http://www.ncbi.nlm.nih.gov/pubmed/7758058

Ozagrel is a thromboxane A2 synthesis inhibitor used for the treatment of cerebral vasospasm and asthma due to its antiplatelet and anti-inflammation properties.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Thromboxane-A synthase 21 Target ID: P24557\|\|\|Q8IUN1\|\|\|Q9HD82 Gene ID: 6916.0 Gene Symbol: TBXAS1 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/14720071	Inhibitor 8297		11.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Bronchial asthma 50 Sources: http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1843.2006.00920_6.x/pdf	Palliative		Approved 8429	DOMENAN Approved Use Unknown
Cerebral vasospasm 9 Sources: http://apps.who.int/medicinedocs/index/assoc/h5778e/h5778e.pdf	Primary		Approved 8429	XANBON Approved Use Cerebral vasospasm and ischaemia following surgical management of subarachnoid haemorrhage.

PubMed

Title	Date	PubMed
Thromboxane A2 and development of genetic hypertension in the Lyon rat strain.	1990 Dec	2147173
Heparin-protamine complexes cause pulmonary hypertension in goats.	1995 Oct	7574058
Effect of sodium ozagrel on the activity of rat CYP2D6.	2007 Nov 14	17651725
Thromboxane synthase mutations in an increased bone density disorder (Ghosal syndrome).	2008 Mar	18264100

Patents

Sample Use Guides

In Vivo Use Guide

1 tablet (200 mg of the active ingredient) at a time, twice a day after breakfast and before bedtime (for asthma). Intravenous infusion of 80mg, twice a day, solute in 500ml normal saline or 5% glucose solution (cerebral vasospasm).

Route of Administration: Other

In Vitro Use Guide

The inﬂuence of ozagrel on platelets aggregation was investigated. Platelet aggregation which was induced by ADP (5 uM) was inhibited by ozagrel. This inhibition was dependent on the concentration of the drug and was significant at 10(−6)–10(−3) M.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 04:19:41 GMT 2023` Edited by `admin` on `Sat Dec 16 04:19:41 GMT 2023`
Record UNII	4X5577N3ET
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OZAGREL SODIUM

Common Name

English

2-PROPENOIC ACID, 3-(4-(1H-IMIDAZOL-1-YLMETHYL)PHENYL)-, SODIUM SALT, (2E)-

Common Name

English

KW-01

Code

English

OZAGREL SODIUM SALT [MI]

Common Name

English

2-PROPENOIC ACID, 3-(4-(1H-IMIDAZOL-1-YLMETHYL)PHENYL)-, SODIUM SALT, (E)-

Common Name

English

SODIUM OZAGREL

Common Name

English

Ozagrel sodium [WHO-DD]

Common Name

English

CATACLOT

Brand Name

English

ATHROMBONE

Common Name

English

2-PROPENOIC ACID, 3-(4-(1H-IMIDAZOL-1-YLMETHYL)PHENYL)-, SODIUM SALT (1:1), (2E)-

Common Name

English

XANBON

Brand Name

English

OZAGREL SODIUM [JAN]

Common Name

English

KADENIN

Common Name

English

Code System Code Type Description

MESH

C034364